New ‘Mini-Brain’ Organoids Offer Hope for Glioblastoma Treatment

Researchers at the Carlos III Health Institute (ISCIII) in Spain, in collaboration with the Francisco de Vitoria University (UFV) and Vithas Hospital Group, have developed patient-derived glioma organoids – three-dimensional, lab-grown “mini-organs” – that closely mimic the characteristics of real brain tumors. This breakthrough promises to accelerate research into glioblastoma, an aggressive and currently incurable form of brain cancer, and pave the way for more personalized therapies.

Understanding Glioblastoma and the Require for Better Models

Glioblastoma is the most common and aggressive type of brain tumor in adults.¹ Despite treatment with surgery, radiation, and chemotherapy, the average life expectancy for patients remains only 15 to 20 months.² A major challenge in developing new treatments is the lack of accurate models that replicate the complexity of these tumors.

The Promise of Glioblastoma Organoids

Organoids are created from human cells and grown in the lab to resemble the structure and function of human organs.² The newly developed glioma organoids offer several key advantages:

• Long-Term Retention of Key Mutations: Unlike traditional 2D cell cultures, these organoids maintain the IDH1 R132H mutation, a critical genetic alteration found in many gliomas, for extended periods.
• Immune Phenotype Replication: The organoids accurately reflect the “cold” immune environment of glioblastoma, characterized by a predominance of myeloid cells and a lack of T lymphocytes, which explains the limited success of some immunotherapies.
• Ultrastructural Complexity: Analysis using transmission electron microscopy (TEM) revealed a greater level of structural detail in the organoids, including neuron-glia interactions and preserved organelles, compared to other cell lines.

Accelerating Drug Discovery and Personalized Medicine

The researchers have developed a unique “pipeline” that combines computational screening with the high-fidelity organoid model. By cross-referencing gene expression profiles of the organoids with drug sensitivity databases, they can prioritize potentially effective therapies for individual patients in a timeframe compatible with clinical practice.²

Preliminary data from this research suggests that two compounds, alectinib and ruxolitinib, warrant further investigation as potential treatments for glioma.²

Looking Ahead

This study represents a significant step towards developing more effective and personalized treatments for glioblastoma. The ability to create patient-specific organoid models will allow researchers to test different therapies and predict which ones are most likely to succeed, ultimately improving outcomes for patients facing this devastating disease.

The Carlos III Health Institute (ISCIII) is a Spanish public health research institute dedicated to improving the health of citizens through research and innovation in health sciences and biomedicine.¹³